Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

No Roferon for You! Another Way for Biotech to Play FOBs Defense?

This article was originally published in RPM Report

Executive Summary

At the beginning of October, Roche announced the discontinuation of the alpha interferon brand Roferon-A. That decision is unremarkable, except that it may have an interesting consequence: protecting Pegasys--Roche's second-generation pegylated recombinant interferon product--from competition once Congress completes work on follow-on biologics. Alpha interferon is sure to be an early target of generic drug manufacturers looking at biosimilar opportunities, along with EPO. A lower-cost interferon alternative certainly wouldn't help Roche's prized Pegasys franchise. In that context, the withdrawal of Roferon-A raises an interesting question: will generics companies be able to pursue follow-on versions of that product now that Roche has withdrawn the product?

You may also be interested in...



Orphaning Biotech? The Impact of Biosimilars on Biotech Investment

An abbreviated follow-on biologics pathway is inevitable, despite the fact that Congress failed to pass legislation in 2007. Will a FOBs pathway adversely impact money flowing into the biotech industry? Unlikely. The impact of the 1983 Orphan Drug Act may be a good model to consider. (This article first appeared in the RPM Report, January 2008).

Orphaning Biotech? The Impact of Biosimilars on Biotech Investment

An abbreviated follow-on biologics pathway is inevitable, despite the fact that Congress failed to pass legislation in 2007. Will a FOBs pathway adversely impact money flowing into the biotech industry? Unlikely. The impact of the 1983 Orphan Drug Act may be a good model to consider.

Orphaning Biotech? The Impact of Biosimilars on Biotech Investment

An abbreviated follow-on biologics pathway is inevitable, despite the fact that Congress failed to pass legislation in 2007. Will a FOBs pathway adversely impact money flowing into the biotech industry? Unlikely. The impact of the 1983 Orphan Drug Act may be a good model to consider.

Related Companies

UsernamePublicRestriction

Register

PS017586

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel